{"id":"NCT00936897","sponsor":"Amgen","briefTitle":"A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates","officialTitle":"A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2011-11","completion":"2012-01","firstPosted":"2009-07-10","resultsPosted":"2012-11-29","lastUpdate":"2013-02-11"},"enrollment":833,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"Ibandronate","otherNames":[]},{"type":"DRUG","name":"Denosumab","otherNames":[]}],"arms":[{"label":"Ibandronate","type":"ACTIVE_COMPARATOR"},{"label":"Denosumab","type":"EXPERIMENTAL"}],"summary":"This is a multi-center, randomized, open-label, parallel group, study being conducted in the United States and in Europe in postmenopausal women. Approximately 800 subjects will be randomized across about 65 sites in a 1:1 ratio to either denosumab 60mg SC Q6M, or ibandronate 150mg PO QM.","primaryOutcome":{"measure":"Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","timeFrame":"Baseline to month 12","effectByArm":[{"arm":"Denosumab 60 mg SC Q6M","deltaMin":2.2,"sd":null},{"arm":"Ibandronate 150 mg PO QM","deltaMin":0.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":17,"exclusionCount":26},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["31776637","23812464"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":410},"commonTop":["Arthralgia","Upper respiratory tract infection"]}}